Mortality in adults with chronic hepatitis B infection in the United States: a population‐based study

Abstract

Background Chronic hepatitis B infection is an important contributor to mortality in the United States, yet impact of available and effective oral antivirals on mortality among infected individuals is unknown. Aims To compare risks and predictors of mortality in a recent time period between those with chronic, prior and no hepatitis B infection. Methods This is a population‐based cohort study of National Health and Nutrition Examination Surveys participants between 1999 and 2014 linked to National Death Index data. Adults aged 20 years or older with hepatitis B serologic testing were included. Outcomes of all‐cause and liver‐related mortality were evaluated using Cox regression. Results Of 39 206 participants, 192 (0.5%) had chronic and 2694 (6.9%) had prior hepatitis B infection. The all‐cause age/sex‐standardised mortality rates for chronic, prior and uninfected were 21.4, 15.1 and 11.8 per 1000 person‐years respectively. Liver‐related mortality occurred at respective rates of 4.1, 0.3 and 0.1 per 1000 person‐years. In multivariable analyses, those with chronic infection had 1.9‐fold (95% CI 1.1‐3.3) increased hazard of all‐cause mortality and 13.3‐fold (95% CI 3.9‐45.5) increased hazard of liver‐related mortality compared to uninfected. Predictors of all‐cause mortality among chronic infection included heavy alcohol use (HR 18.3, 95% CI 3.3‐100.6) and higher alanine aminotransferase (HR 1.02, 95% CI 1.00‐1.03). Conclusions Mortality among adults living with chronic hepatitis B infection still exceeds that of uninfected despite availability of improved therapeutics. Identification of chronic infection, initiation of treatment among eligible and modulation of co‐factors for disease progression are needed to improve survival.